Red Pills in the Real World — Osmind’s Ketamine Study

Osmind software runs the largest network of mental health clinics, and this allows them to perform the largest studies of real-world outcomes for novel therapies, as with this peer-reviewed study of the use of ketamine to treat depression.

“Real-world data collection is taking off in the ketamine space, and it’s clear Osmind are field leaders here,” said Robin Carhart-Harris, UCSF Psychedelics Division.

• 54% response rate and 30% remission rate
• 70% experienced an overall improvement in suicidal ideation
• Durability: 80% retained response at 4 weeks and 60% at 8 weeks

More details and links here.